EU/3/09/641

Table of contents

About

On 15 May 2009, orphan designation (EU/3/09/641) was granted by the European Commission to Atlantic Healthcare Limited, United Kingdom, for alicaforsen for the treatment of pouchitis.

In July 2013, Atlantic Healthcare Limited changed name to Atlantic Healthcare plc.

The sponsorship was transferred to Atlantic Pharmaceuticals (Holdings) Ltd, United Kingdom, in November 2017.

The sponsorship was transferred to Atlantic Healthcare Europe B.V., the Netherlands, in April 2019.

Key facts

Active substance
Alicaforsen
Disease / condition
Treatment of pouchitis
Date of decision
15/05/2009
Outcome
Positive
Orphan decision number
EU/3/09/641

Sponsor's contact details

Atlantic Healthcare Europe B.V.
Zekeringstraat 17a 
Amsterdam 
Noord-Holland 
1014 BM 
Netherlands
Tel. +31  0205708900
E-mail: info@atlantichc.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating